Home
|
Inbox
|
Search
|
View Abstract
Respiratory Medications Used in COPD Patients from Seven Latin American Countries: The LASSYC Study
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A3264 - Respiratory Medications Used in COPD Patients from Seven Latin American Countries: The LASSYC Study
Author Block: M. Montes de Oca1, A. Casas2, A. B. Menezes3, L. Ugalde Gamboa4, L. Ramirez5, A. Ramirez-Venegas6, L. H. Mendoza7, A. M. Lopez8, M. Miravitlles9; 1Hospital Universitario de Caracas, Caracas, Venezuela, Bolivarian Republic of, 2Fundacion Neumologica Colombiana, Bogota, Colombia, 3Faculty of Medicine, Pelotas, Brazil, 4Clínica Americana, San José, Costa Rica, 5AstraZeneca, Escazú, Costa Rica, 6Departamento de Investigacion en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 7Hospital Clinico Universidad De Chile, Santiago, Chile, 8Hospital Nacional de Clínicas de Córdoba, Cordoba, Argentina, 9Pneumology, Hospital Vall d'Hebron, Barcelona, Spain.
Respiratory medications used in COPD patients from seven Latin American countries: The LASSYC Study
Maria Montes de Oca1, Alejandro Casas2; Ana Menezes3, Luis Ugalde4, Victorina López5, Larissa Ramirez6, Alejandra Ramírez-Venegas7, Laura Mendoza8; Ana López9, Marc Miravitlles10
1Universidad Central de Venezuela, Venezuela; 2Fundación Neumológica Colombiana, Colombia; 3Federal University of Pelotas, Brazil; 4Clínica Americana, San José, Costa Rica; 5 Universidad de la República, Uruguay; 6Astra Zeneca, Costa Rica; 7Instituto Nacional de Enfermedades Respiratorias, Mexico,
8Hospital Clínico Universidad de Chile, Chile; 9Hospital Nacional de Clínicas de Córdoba, Argentina; 10Department of Pneumology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Background: Despite the changes in COPD guidelines recommendations and the emergence of new inhaled drugs, there is a considerable gap between the optimal treatment and the real-life prescribing patterns. Limited information exists regarding the real-life medication used in COPD patients from Latin America.
Objective: To describe the type of respiratory medication used in COPD patients in general and according to the GOLD-2013 categories from Latin American region.
Methods: 795 COPD patients participated in an observational, cross-sectional multinational study. The type of medication was assessed as short-acting β-agonists or muscarinic antagonists (SABA or SAMA only), long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, and other.
Results: 59.6% of patients were male, with mean age 69.5±8.7 years, and post-bronchodilator FEV1 50.0±18.6%. In general, the ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medication used. Only 6.4% of patients were using LABA, 5.8% LAMA and 11.3% LABA/LAMA. The type of medication used in each GOLD-2013 category is shown in the figure.
Conclusion: COPD management in Latin America does not follow the GOLD recommendations and there is an overuse of ICS. Better efforts are needed to improve knowledge on COPD management in clinical practice in the region and for giving access to COPD patients to the most appropriate medication regimens.
Author Block: M. Montes de Oca1, A. Casas2, A. B. Menezes3, L. Ugalde Gamboa4, L. Ramirez5, A. Ramirez-Venegas6, L. H. Mendoza7, A. M. Lopez8, M. Miravitlles9; 1Hospital Universitario de Caracas, Caracas, Venezuela, Bolivarian Republic of, 2Fundacion Neumologica Colombiana, Bogota, Colombia, 3Faculty of Medicine, Pelotas, Brazil, 4Clínica Americana, San José, Costa Rica, 5AstraZeneca, Escazú, Costa Rica, 6Departamento de Investigacion en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 7Hospital Clinico Universidad De Chile, Santiago, Chile, 8Hospital Nacional de Clínicas de Córdoba, Cordoba, Argentina, 9Pneumology, Hospital Vall d'Hebron, Barcelona, Spain.
Respiratory medications used in COPD patients from seven Latin American countries: The LASSYC Study
Maria Montes de Oca1, Alejandro Casas2; Ana Menezes3, Luis Ugalde4, Victorina López5, Larissa Ramirez6, Alejandra Ramírez-Venegas7, Laura Mendoza8; Ana López9, Marc Miravitlles10
1Universidad Central de Venezuela, Venezuela; 2Fundación Neumológica Colombiana, Colombia; 3Federal University of Pelotas, Brazil; 4Clínica Americana, San José, Costa Rica; 5 Universidad de la República, Uruguay; 6Astra Zeneca, Costa Rica; 7Instituto Nacional de Enfermedades Respiratorias, Mexico,
8Hospital Clínico Universidad de Chile, Chile; 9Hospital Nacional de Clínicas de Córdoba, Argentina; 10Department of Pneumology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Background: Despite the changes in COPD guidelines recommendations and the emergence of new inhaled drugs, there is a considerable gap between the optimal treatment and the real-life prescribing patterns. Limited information exists regarding the real-life medication used in COPD patients from Latin America.
Objective: To describe the type of respiratory medication used in COPD patients in general and according to the GOLD-2013 categories from Latin American region.
Methods: 795 COPD patients participated in an observational, cross-sectional multinational study. The type of medication was assessed as short-acting β-agonists or muscarinic antagonists (SABA or SAMA only), long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, and other.
Results: 59.6% of patients were male, with mean age 69.5±8.7 years, and post-bronchodilator FEV1 50.0±18.6%. In general, the ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medication used. Only 6.4% of patients were using LABA, 5.8% LAMA and 11.3% LABA/LAMA. The type of medication used in each GOLD-2013 category is shown in the figure.
Conclusion: COPD management in Latin America does not follow the GOLD recommendations and there is an overuse of ICS. Better efforts are needed to improve knowledge on COPD management in clinical practice in the region and for giving access to COPD patients to the most appropriate medication regimens.
|
Home
|
Inbox
|
Search
|